Enliven Therapeutics (NASDAQ:ELVN) Stock Rating Lowered by Wall Street Zen

Key Points

• Wall Street Zen downgraded Enliven Therapeutics to “sell” from “hold,” contrasting with six other analysts’ Buy ratings. MarketBeat data shows a consensus “Moderate Buy” rating and an average price target of $72.67.
• Enliven reported a quarterly loss of $0.49 per share, missing the $0.39 consensus estimate; analysts expect a full-year loss of $1.57 per share. Shares opened at $60.46, near their 52-week high of $62.32.
• Company insiders sold 190,831 shares worth roughly $11.0 million during the last quarter, including a director’s $9.6 million sale under a pre-arranged Rule 10b5-1 plan. Institutional investors own 95.08% of the stock.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) was downgraded by equities researchers at Wall Street Zen from a "hold" rating to a "sell" rating in a research note issued to investors on Saturday.

ELVN has been the topic of several other research reports. HC Wainwright increased their price target on Enliven Therapeutics from $56.00 to $64.00 and gave the company a "buy" rating in a report on Thursday, July 9th. The Goldman Sachs Group boosted their price objective on shares of Enliven Therapeutics from $67.00 to $80.00 and gave the company a "buy" rating in a research report on Thursday. Guggenheim reduced their target price on shares of Enliven Therapeutics from $80.00 to $78.00 and set a "buy" rating on the stock in a research note on Thursday. JonesTrading raised their target price on shares of Enliven Therapeutics from $45.00 to $70.00 and gave the stock a "buy" rating in a report on Monday, June 29th. Finally, Mizuho lifted their price target on shares of Enliven Therapeutics from $45.00 to $62.00 and gave the stock an "outperform" rating in a research note on Tuesday, June 2nd. Six research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Enliven Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $72.67.

Enliven Therapeutics Price Performance

Shares of ELVN stock opened at $60.46 on Friday. Enliven Therapeutics has a 1 year low of $14.78 and a 1 year high of $62.32. The stock's 50 day simple moving average is $48.62 and its two-hundred day simple moving average is $39.68. The company has a market cap of $3.68 billion, a PE ratio of -36.20 and a beta of 0.27.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.10). Equities research analysts expect that Enliven Therapeutics will post -1.57 EPS for the current year.

Insider Activity at Enliven Therapeutics

In other Enliven Therapeutics news, Director Mika K. Derynck sold 158,795 shares of the stock in a transaction on Tuesday, August 4th. The stock was sold at an average price of $60.21, for a total value of $9,561,046.95. Following the sale, the director owned 87,373 shares in the company, valued at $5,260,728.33. This trade represents a 64.51% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Benjamin Hohl sold 6,018 shares of Enliven Therapeutics stock in a transaction on Friday, July 17th. The stock was sold at an average price of $52.64, for a total value of $316,787.52. Following the sale, the chief financial officer owned 46,054 shares of the company's stock, valued at approximately $2,424,282.56. This trade represents a 11.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 190,831 shares of company stock worth $10,991,723 in the last quarter. 3.00% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. KBC Group NV bought a new stake in Enliven Therapeutics during the 1st quarter valued at about $38,000. Mirae Asset Global Investments Co. Ltd. grew its stake in Enliven Therapeutics by 25.9% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company's stock worth $44,000 after acquiring an additional 594 shares in the last quarter. BNP Paribas Financial Markets increased its position in shares of Enliven Therapeutics by 33.3% during the second quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company's stock worth $75,000 after acquiring an additional 930 shares during the period. Los Angeles Capital Management LLC bought a new stake in shares of Enliven Therapeutics during the fourth quarter valued at approximately $83,000. Finally, Quantbot Technologies LP raised its stake in shares of Enliven Therapeutics by 47.1% during the second quarter. Quantbot Technologies LP now owns 4,477 shares of the company's stock valued at $90,000 after acquiring an additional 1,434 shares in the last quarter. 95.08% of the stock is currently owned by institutional investors.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source